|
|
Volumn 10, Issue 15, 2005, Pages 1031-1039
|
|
Keynote review: Is declining innovation in the pharmaceutical industry a myth?
a,b
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ACETYLSALICYLIC ACID;
ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT;
AMLODIPINE BESYLATE;
ATORVASTATIN;
BENDROFLUMETHIAZIDE;
CARBIDOPA PLUS LEVODOPA;
CHLOROTHIAZIDE;
CIMETIDINE;
CISAPRIDE;
CLOTRIMAZOLE;
DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;
ERYTHROPOIETIN;
ETANERCEPT;
ETHINYLESTRADIOL;
FLUCONAZOLE;
FLUOXETINE;
FUROSEMIDE;
GLIPIZIDE;
HALOPERIDOL;
HISTAMINE H2 RECEPTOR ANTAGONIST;
IMATINIB;
INDOMETACIN;
INFLUENZA VACCINE;
NONSTEROID ANTIINFLAMMATORY AGENT;
PRAZOSIN;
RECOMBINANT ERYTHROPOIETIN;
SILDENAFIL;
TERFENADINE;
TOLBUTAMIDE;
WARFARIN;
DEPRESSION;
DRUG APPROVAL;
DRUG COST;
DRUG FATALITY;
DRUG INDUSTRY;
DRUG MARKETING;
ERECTILE DYSFUNCTION;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
HYPERTENSION;
NON INSULIN DEPENDENT DIABETES MELLITUS;
PARKINSON DISEASE;
PSYCHOSIS;
PULMONARY HYPERTENSION;
QT PROLONGATION;
REVIEW;
RISK BENEFIT ANALYSIS;
STOMACH ULCER;
COST-BENEFIT ANALYSIS;
DEVICE APPROVAL;
DRUG INDUSTRY;
EFFICIENCY;
LEGISLATION, DRUG;
RESEARCH;
UNITED STATES;
|
|
EID: 23044491985
PISSN: 13596446
EISSN: None
Source Type: Journal
DOI: 10.1016/S1359-6446(05)03524-5 Document Type: Review |
|
Times cited : (101)
|
|
References (4)
|
